课题基金 / 基金详情

PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2 BY INTRAVENOUSLY

PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2 BY INTRAVENOUSLY
间歇性静脉注射重组人白介素-2 的 II 期研究
批准号：
6297758
负责人：
RONALD T. MITSUYASU
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6297758
关键词：
AIDS therapy CD4 molecule antiAIDS agent antiviral agents clinical research clinical trial phase I drug administration rate /duration drug administration routes drug screening /evaluation drug tolerance human subject human therapy evaluation interleukin 2 intravenous administration leukocyte count microorganism disease chemotherapy quality of life recombinant proteins

项目摘要

项目成果

RONALD T. MITSUYASU的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To compare two different routes of intermittently administered rhIL-2 with a highly active antiretroviral regimen to highly active antiretroviral therapy alone with respect to the proportion of subjects achieving greater than or equal to 50% increase in CD4 counts abouve prerandomization baseline values after one year of rhIL-2 and the rate of change in CD4 counts. This study will compare the safety, tolerance, and effect on quality of life of these regimens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
South American Prevention of HIV Research Training Program (SAPHIR)
South American Prevention of HIV Research Training Program (SAPHIR)
海外基金